Reducing the Global Impact of Diabetes

Diamune’s cutting-edge and proprietary Fc-fusion protein technology has allowed the development of products that are changing the way diabetes is treated and prevented.

Diamune Pipeline

candidate
indication
mechanism
partner
Discovery
Pre-Clinical
Phase 1
Phase II
Phase III
Market
AKS-440
Once-a-Week Insulin T1D (+ T2D)
Ultra long-acting insulin Fc analog
Indication: Once-a-Week Insulin T1D (+ T2D)
Pre-Clinical

AKS-440 is a novel human insulin candidate based on an Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. Diamune Therapeutics, Inc. has licensed this patent from Akston Biosciences Corporation to continue the development of this therapy. It is currently in pre-clinical development.

Patent Info
Patent Granted
PRESS RELEASE
Akston Biosciences Receives U.S. Patent for Once-A-Week Human Insulin
AKS-107
T1D Prevention/Intervention
Inactive insulin antigen Fc analog to interrupt insulin-specific autoimmunity
Indication: T1D Prevention/Intervention
Pre-Clinical

AKS-107 is an Fc-insulin fusion protein designed to interrupt the process leading to insulin autoimmunity. Diamune Therapeutics, Inc. has licensed this patent from Akston Biosciences Corporation to continue the development that was begun with a partnership with the Helmsley Charitable Trust and the National Institutes of Health (NIH) in the early development stages.

Patent Info
Patent Granted
PAPERS
An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes

AKS-440: Once-a-week injectable insulin for treating diabetes

AKS-107: An immunotherapeutic for Type 1 Diabetes Prevention